TATVA

Tatva Chintan Pharma Chem Share Price

₹954.65 -1.85 (-0.19%)

10 Jul, 2025 06:13

SIP TrendupStart SIP in TATVA

Start SIP

Performance

  • Low
  • ₹948
  • High
  • ₹974
  • 52 Week Low
  • ₹621
  • 52 Week High
  • ₹1,200
  • Open Price₹952
  • Previous Close₹957
  • Volume29,731

Investment Returns

  • Over 1 Month + 2.35%
  • Over 3 Month + 43.71%
  • Over 6 Month + 8.3%
  • Over 1 Year -17.6%
SIP Lightning

Smart Investing Starts Here Start SIP with Tatva Chintan Pharma Chem for Steady Growth!

Invest Now

Tatva Chintan Pharma Chem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 390.9
  • PEG Ratio
  • -4.8
  • Market Cap Cr
  • 2,233
  • P/B Ratio
  • 3
  • Average True Range
  • 39.21
  • EPS
  • 2.44
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 24.73
  • RSI
  • 53.65
  • MFI
  • 77.43

Tatva Chintan Pharma Chem Financials

Tatva Chintan Pharma Chem Technicals

EMA & SMA

Current Price
₹954.65
-1.85 (-0.19%)
pointer
  • stock-down_img
  • Bearish Moving Average 5
  • stock-up_img
  • Bullish Moving Average 11
  • 20 Day
  • ₹949.65
  • 50 Day
  • ₹897.32
  • 100 Day
  • ₹857.06
  • 200 Day
  • ₹885.55

Resistance and Support

959.03 Pivot Speed
  • R3 996.52
  • R2 985.48
  • R1 970.07
  • S1 943.62
  • S2 932.58
  • S3 917.17

What's your outlook on Tatva Chintan Pharma Chem?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Tatva Chintan Pharma manufactures specialty chemicals, including phase transfer catalysts, pharmaceutical intermediates, and electrolytes for batteries. With global operations and R&D capabilities, it serves industries like pharmaceuticals, agrochemicals, and automotive, providing innovative chemical solutions.

Tatva Chintan Pharma Chem has an operating revenue of Rs. 382.71 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of 2% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 13% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 11 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Chemicals-Basic and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Tatva Chintan Pharma Chem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-02 Audited Results & Final Dividend
2025-01-28 Quarterly Results
2024-10-25 Quarterly Results
2024-07-24 Quarterly Results
2024-05-03 Audited Results & Final Dividend
Date Purpose Remarks
2022-09-09 FINAL Rs.2.00 per share(20%)Final Dividend
View More

Tatva Chintan Pharma Chem F&O

Tatva Chintan Pharma Chem Shareholding Pattern

72.02%
5.34%
3.3%
16.92%
2.42%

About Tatva Chintan Pharma Chem

  • NSE Symbol
  • TATVA
  • BSE Symbol
  • 543321
  • Chairman & Managing Director
  • Mr. Chintan Nitinkumar Shah
  • ISIN
  • INE0GK401011

Similar Stocks to Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem FAQs

Tatva Chintan Pharma Chem share price is ₹954 As on 10 July, 2025 | 05:59

The Market Cap of Tatva Chintan Pharma Chem is ₹2233.1 Cr As on 10 July, 2025 | 05:59

The P/E ratio of Tatva Chintan Pharma Chem is 390.9 As on 10 July, 2025 | 05:59

The PB ratio of Tatva Chintan Pharma Chem is 3 As on 10 July, 2025 | 05:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23